BackgroundDuvelisib is the first FDA-approved oral dual inhibitor of phosphatidylinositol-3-kinase PI3K-delta (PI3K-δ) and PI3K-gamma (PI3K-γ). Although many clinical studies support the efficacy of duvelisib, the safety of duvelisib remains with great attention. This systematic review and meta-analysis aimed to evaluate the safety and efficacy of duvelisib in treating different relapsed or refractory (RR) lymphoid neoplasm types.MethodsWe searched prospective clinical trials from PUBMED, EMBASE, Cochrane Library, and ClinicalTrials.gov. For efficacy analysis, Overall response rate (ORR), complete response rate (CR), partial response rate (PR), rate of stable disease (SDR), rate of progressive disease (PDR), median progression-free survival...
BACKGROUNDPhosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microen...
Duvelisib is an orally active dual inhibitor of PI3K-δ and PI3K-γ in clinical development in hematol...
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmenta...
Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evalu...
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase delta ...
PURPOSE: In the phase III DUO trial, duvelisib, an oral dual PI3K-δ,γ inhibitor, demonstrated signif...
Duvelisib (Copiktra®) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3K	...
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ and ...
PURPOSE: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple ...
Phosphoinositide 3-kinase-delta (PI3Kδ) inhibitors are active in lymphoid malignancies, though assoc...
Chronic lymphocytic leukemia (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies ...
The treatment (i.e. therapy and management) of chronic lymphocytic leukemia (i.e. the disease) has b...
<p><b>A. Growth inhibition (GI<sub>50</sub>) of duvelisib across the panel of twenty cell lines</b>....
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) repre...
Duvelisib, an oral dual inhibitor of PI3K-δ and PI3K-γ, is in phase III trials for the treatment of ...
BACKGROUNDPhosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microen...
Duvelisib is an orally active dual inhibitor of PI3K-δ and PI3K-γ in clinical development in hematol...
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmenta...
Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evalu...
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase delta ...
PURPOSE: In the phase III DUO trial, duvelisib, an oral dual PI3K-δ,γ inhibitor, demonstrated signif...
Duvelisib (Copiktra®) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3K	...
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ and ...
PURPOSE: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple ...
Phosphoinositide 3-kinase-delta (PI3Kδ) inhibitors are active in lymphoid malignancies, though assoc...
Chronic lymphocytic leukemia (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies ...
The treatment (i.e. therapy and management) of chronic lymphocytic leukemia (i.e. the disease) has b...
<p><b>A. Growth inhibition (GI<sub>50</sub>) of duvelisib across the panel of twenty cell lines</b>....
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) repre...
Duvelisib, an oral dual inhibitor of PI3K-δ and PI3K-γ, is in phase III trials for the treatment of ...
BACKGROUNDPhosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microen...
Duvelisib is an orally active dual inhibitor of PI3K-δ and PI3K-γ in clinical development in hematol...
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmenta...